https://mindmedicinelaw.com/briefing/psilocybin-in-psychiatry-clinical-and-public-health-policy-outlook-20261101-55555The Psychedelic Journalen2026-11-01T15:06:55.368838+00:00Psilocybin in Psychiatry: Clinical and Public Health Policy Outlookpsilocybin, psychiatry, public health, clinical trials, policy, regulation, safety, access equity, mental health, oregon psilocybin programhttps://mindmedicinelaw.com/briefing/psilocybin-s-molecular-links-to-depression-and-schizophrenia-pathways-20261101-55573The Psychedelic Journalen2026-11-01T15:05:50.369398+00:00Psilocybin’s Molecular Links to Depression and Schizophrenia Pathwayspsilocybin, depression, schizophrenia, molecular pathways, biomarkers, clinical trial design, precision medicine, psychedelic research, bdnf, policy implicationshttps://mindmedicinelaw.com/briefing/psilocybin-alters-decision-making-under-uncertainty-insights-from-elife-study-20261030-55491The Psychedelic Journalen2026-11-01T15:07:23.383244+00:00Psilocybin Alters Decision-Making Under Uncertainty: Insights from eLife Studypsilocybin, decision-making, uncertainty, cortical processing, mechanism of action, clinical trial design, policy implications, risk assessment, psychedelic researchhttps://mindmedicinelaw.com/briefing/chiral-capillary-electrophoresis-sensitivity-advances-for-psychedelic-drug-analy-20261030-55507The Psychedelic Journalen2026-11-01T15:07:08.687615+00:00Chiral Capillary Electrophoresis: Sensitivity Advances for Psychedelic Drug Analysischiral capillary electrophoresis, psychedelic drug analysis, enantiomer detection, pharmaceutical quality control, regulatory compliance, clinical trial methods, mass spectrometry detection, enantiomeric purity, analytical chemistry advances, psychedelic manufacturinghttps://mindmedicinelaw.com/briefing/helus-pharma-s-psychedelic-adjunctive-progresses-in-u-s-phase-3-trials-20261030-55525The Psychedelic Journalen2026-11-01T15:06:44.035088+00:00Helus Pharma's Psychedelic Adjunctive Progresses in U.S. Phase 3 Trialshelus pharma, psychedelic adjunctive, phase 3 clinical trial, psych congress 2026, fda regulatory pathway, psychiatric treatment, drug-drug interactions, psychedelic medicine, clinical integrationhttps://mindmedicinelaw.com/briefing/mechanistic-uncertainty-in-psychiatric-drugs-implications-for-psychedelic-resear-20261030-55487The Psychedelic Journalen2026-11-01T15:06:30.755706+00:00Mechanistic Uncertainty in Psychiatric Drugs: Implications for Psychedelic Research and Policypsychiatric drug mechanisms, psychedelic research, clinical trial design, regulatory policy, informed consent ethics, ketamine, psilocybin, mechanistic studies, FDA, placebo responsehttps://mindmedicinelaw.com/briefing/psilocybin-modulates-decision-making-and-cortical-processing-in-animal-models-20261030-55488The Psychedelic Journalen2026-11-01T15:06:17.569518+00:00Psilocybin Modulates Decision-Making and Cortical Processing in Animal Modelspsilocybin, decision-making, reinforcement learning, cortical processing, animal model, preclinical research, clinical trial design, psychedelic therapy, neural encodinghttps://mindmedicinelaw.com/briefing/psilocybin-modulates-learning-under-uncertainty-in-rodent-study-20261030-55495The Psychedelic Journalen2026-11-01T15:06:04.335237+00:00Psilocybin Modulates Learning Under Uncertainty in Rodent Studypsilocybin, rodent study, reinforcement learning, cortical processing, uncertainty, preclinical research, neural encoding, clinical trial design, meta-learning, psychedelic mechanismshttps://mindmedicinelaw.com/briefing/trump-executive-order-fast-tracks-psilocybin-ibogaine-access-in-us-20261030-55162The Psychedelic Journalen2026-10-31T15:05:54.050372+00:00Trump Executive Order Fast-Tracks Psilocybin, Ibogaine Access in USpsilocybin policy, ibogaine regulation, executive order psychedelics, federal psychedelic law, mental health innovation, clinical trial acceleration, controlled substances act, public health policy, psychedelic therapy accesshttps://mindmedicinelaw.com/briefing/bridging-efficacy-and-real-world-practice-in-psychedelic-trials-20261030-55107The Psychedelic Journalen2026-10-30T22:05:37.144623+00:00Bridging Efficacy and Real-World Practice in Psychedelic Trialspsychedelic clinical trials, real-world effectiveness, psilocybin therapy, mdma-assisted therapy, fda regulation, payer adoption, implementation science, oregon psilocybin program, integration support, trial designhttps://mindmedicinelaw.com/briefing/music-selection-practices-in-psychedelic-therapy-new-survey-insights-20261029-55164The Psychedelic Journalen2026-10-31T22:06:50.651779+00:00Music Selection Practices in Psychedelic Therapy: New Survey Insightspsychedelic-assisted therapy, music selection, playlist integration, clinical protocols, survey research, post-session listening, patient outcomes, therapy best practices, session music, clinical trialshttps://mindmedicinelaw.com/briefing/cultural-adaptation-of-trauma-therapies-for-indigenous-peoples-in-north-america-20261029-55199The Psychedelic Journalen2026-10-31T22:06:37.295022+00:00Cultural Adaptation of Trauma Therapies for Indigenous Peoples in North Americacultural adaptation, indigenous trauma, psychedelic-assisted therapy, north america, wise practices, clinical guidelines, community collaboration, trauma interventions, public health, regulatory policyhttps://mindmedicinelaw.com/briefing/establishing-interventional-psychiatry-clinics-new-guidance-for-psychedelic-ther-20261029-55267The Psychedelic Journalen2026-10-31T22:06:24.724496+00:00Establishing Interventional Psychiatry Clinics: New Guidance for Psychedelic Therapiesinterventional psychiatry, psychedelic-assisted therapy, clinic development, regulatory compliance, staffing models, safety protocols, policy framework, clinical integration, ketamine clinics, future of psychiatryhttps://mindmedicinelaw.com/briefing/tryptophan-metabolism-gut-brain-axis-and-depression-implications-for-psychedelic-20261029-55163The Psychedelic Journalen2026-10-31T15:07:57.891677+00:00Tryptophan Metabolism, Gut–Brain Axis, and Depression: Implications for Psychedelic Researchtryptophan metabolism, gut-brain axis, depression heterogeneity, serotonin pathways, psychedelic research, multi-omics biomarkers, microbiome interventions, precision psychiatry, clinical trial designhttps://mindmedicinelaw.com/briefing/hhs-proposes-overhaul-of-federal-urine-drug-testing-guidelines-20261029-55141The Psychedelic Journalen2026-10-31T15:07:19.926218+00:00HHS Proposes Overhaul of Federal Urine Drug Testing Guidelinesfederal drug testing, HHS guidelines, psychedelics policy, psilocybin, MDMA, workplace compliance, clinical research risk, federal employment law, public health policyhttps://mindmedicinelaw.com/briefing/psilocybin-in-aud-and-depression-cognitive-and-clinical-effects-in-pilot-rct-20261029-55165The Psychedelic Journalen2026-10-31T15:07:04.963435+00:00Psilocybin in AUD and Depression: Cognitive and Clinical Effects in Pilot RCTpsilocybin, alcohol use disorder, major depressive disorder, cognitive flexibility, cognitive stability, randomized controlled trial, mechanism of action, pilot study, clinical outcomes, psychedelic therapyhttps://mindmedicinelaw.com/briefing/sv2a-synaptic-density-and-depression-chronicity-not-severity-drives-biomarker-si-20261029-55197The Psychedelic Journalen2026-10-31T15:06:51.115000+00:00SV2A Synaptic Density and Depression: Chronicity, Not Severity, Drives Biomarker Signalsv2a, synaptic density, major depressive disorder, biomarkers, pet imaging, psychedelic research, clinical trial endpoints, regulatory strategy, depression chronicityhttps://mindmedicinelaw.com/briefing/hhs-proposes-revisions-to-federal-oral-fluid-drug-testing-guidelines-20261029-55142The Psychedelic Journalen2026-10-31T15:06:36.653601+00:00HHS Proposes Revisions to Federal Oral Fluid Drug Testing Guidelineshhs, oral fluid drug testing, federal workplace, psychedelics, clinical trial risks, employment law, detection windows, policy update, safety-sensitive positionshttps://mindmedicinelaw.com/briefing/nanomolar-dmt-detection-field-effect-sensor-breakthrough-for-clinical-and-public-20261029-55201The Psychedelic Journalen2026-10-31T15:06:21.639919+00:00Nanomolar DMT Detection: Field-Effect Sensor Breakthrough for Clinical and Public Health Usedmt detection, field-effect transistor sensor, psychedelic biomarkers, clinical trial monitoring, public health surveillance, chemical activation, point-of-care testing, regulatory compliance, nanomolar sensitivityhttps://mindmedicinelaw.com/briefing/psilocybin-s-multi-scale-brain-effects-in-macaques-translational-insights-20261029-55028The Psychedelic Journalen2026-10-30T22:07:12.002799+00:00Psilocybin’s Multi-Scale Brain Effects in Macaques: Translational Insightspsilocybin, non-human primate research, macaque brain, translational neuroscience, clinical trial design, fda regulatory review, neuroimaging, preclinical models, psychedelic safetyhttps://mindmedicinelaw.com/briefing/psychedelics-and-disorders-of-consciousness-trial-design-challenges-in-the-us-an-20261029-55106The Psychedelic Journalen2026-10-30T22:06:57.926373+00:00Psychedelics and Disorders of Consciousness: Trial Design Challenges in the US and EUpsychedelic clinical trials, disorders of consciousness, trial design challenges, fda guidance, surrogate consent, neuroimaging endpoints, ethical issues, regulatory barriers, psilocybin research, dmt trialshttps://mindmedicinelaw.com/briefing/virtual-reality-integration-in-ketamine-therapy-us-chart-review-insights-20261029-55109The Psychedelic Journalen2026-10-30T22:06:40.576721+00:00Virtual Reality Integration in Ketamine Therapy: US Chart Review Insightsvirtual reality, ketamine therapy, psychedelic-assisted therapy, digital therapeutics, retrospective chart review, clinical protocols, FDA regulation, tolerability, mental health innovationhttps://mindmedicinelaw.com/briefing/psychedelics-for-substance-use-disorders-evidence-mechanisms-and-gaps-20261029-55027The Psychedelic Journalen2026-10-30T22:05:52.342207+00:00Psychedelics for Substance Use Disorders: Evidence, Mechanisms, and Gapspsychedelics, substance use disorder, psilocybin, clinical trials, neuroplasticity, ibogaine, ketamine, addiction treatment, policy, mechanismshttps://mindmedicinelaw.com/briefing/deep-brain-stimulation-for-anorexia-nervosa-efficacy-targets-and-challenges-20261028-55031The Psychedelic Journalen2026-10-30T22:07:42.964765+00:00Deep Brain Stimulation for Anorexia Nervosa: Efficacy, Targets, and Challengesdeep brain stimulation, anorexia nervosa, treatment-resistant, neuroanatomical targets, connectome-guided neuromodulation, clinical trials, ethical challenges, ai-assisted neuromodulation, device regulationhttps://mindmedicinelaw.com/briefing/torpor-depression-link-implications-for-neuroscience-and-trials-20261028-55046The Psychedelic Journalen2026-10-30T22:07:27.792988+00:00Torpor-Depression Link: Implications for Neuroscience and Trialstorpor, depressive disorders, animal models, clinical trial design, psychedelic research, circadian biology, neuroplasticity, translational neuroscience, biomarkers, regulatory implicationshttps://mindmedicinelaw.com/briefing/mdma-enhanced-exposure-therapy-trial-in-u-s-va-outpatient-care-20261027-55184The Psychedelic Journalen2026-10-31T15:06:07.603869+00:00MDMA-Enhanced Exposure Therapy Trial in U.S. VA Outpatient Caremdma-assisted therapy, ptsd, veterans affairs, clinical trial design, exposure therapy, telehealth, masking integrity, psychedelic research, policy implicationshttps://mindmedicinelaw.com/briefing/intranasal-mebufotenin-trial-for-depression-clinical-and-policy-implications-20261026-55594The Psychedelic Journalen2026-11-01T15:05:35.534521+00:00Intranasal Mebufotenin Trial for Depression: Clinical and Policy Implicationsmebufotenin, intranasal administration, treatment-resistant depression, psychedelic clinical trials, regulatory implications, novel psychedelics, public health policy, trial design, safety and efficacyhttps://mindmedicinelaw.com/briefing/low-dose-ketamine-modulates-brain-entropy-in-trd-neuroimaging-evidence-20261026-55055The Psychedelic Journalen2026-10-30T22:06:08.114135+00:00Low-Dose Ketamine Modulates Brain Entropy in TRD: Neuroimaging Evidenceketamine, brain entropy, treatment-resistant depression, neuroimaging, biomarkers, psychedelic therapy, clinical trials, mechanism of action, rapid antidepressant, translational neurosciencehttps://mindmedicinelaw.com/briefing/india-s-first-public-interventional-psychiatry-service-integrates-psychedelic-th-20261023-55001The Psychedelic Journalen2026-10-30T22:06:25.460169+00:00India’s First Public Interventional Psychiatry Service Integrates Psychedelic Therapiesinterventional psychiatry, psychedelic therapy, india public health, neuromodulation, teaching hospital, clinical integration, regulatory policy, mental health innovation, low- and middle-income countrieshttps://mindmedicinelaw.com/briefing/peer-reviewed-evidence-lsd-microdosing-and-cognitive-enhancement-20261020-55427The Psychedelic Journalen2026-10-31T22:06:11.378158+00:00Peer-Reviewed Evidence: LSD Microdosing and Cognitive Enhancementlsd microdosing, cognitive enhancement, psychedelic research, clinical trials, public health policy, neuroplasticity, regulatory implications, safety profile, schedule i substanceshttps://mindmedicinelaw.com/briefing/ketamine-and-buprenorphine-for-suicidal-crisis-u-s-clinical-implications-20261019-55270The Psychedelic Journalen2026-10-31T15:07:46.057668+00:00Ketamine and Buprenorphine for Suicidal Crisis: U.S. Clinical Implicationsketamine, buprenorphine, suicidal crisis, psychiatric care, clinical trials, policy implications, rapid-acting antidepressants, safety concerns, outpatient transition, mental health protocolshttps://mindmedicinelaw.com/briefing/sex-specific-cognitive-effects-of-lsd-microdosing-policy-and-research-implicatio-20261019-55269The Psychedelic Journalen2026-10-31T15:07:31.864565+00:00Sex-Specific Cognitive Effects of LSD Microdosing: Policy and Research Implicationslsd microdosing, sex differences, cognitive benefits, psychedelic research, clinical trial design, regulatory policy, public health, women's health, neuroscience, personalized medicine